The age of enlightenment in melanoma immunotherapy
Abstract An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously treated or untreated advanced melanoma who received ipilimumab and nivolumab as con...
Збережено в:
| Автор: | |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMJ Publishing Group
2018-08-01
|
| Серія: | Journal for ImmunoTherapy of Cancer |
| Предмети: | |
| Онлайн доступ: | http://link.springer.com/article/10.1186/s40425-018-0397-8 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|